Lyell Immunopharma stock
LYELNASDAQLyell Immunopharma, Inc., HealthcareISIN US55083R2031
33Score 33 out of 100, Weak
Price and trend
55 / 100
Price history
−11% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 4.8% below it.
Since May 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 78).
The price is 59% below its 52-week high. Largest decline in 5 years: 98% (September 2021 to October 2026).
Chart figures for advanced users
- SMA 50$10.99
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$16.43
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)78
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.51
- The lowest closing price of the last twelve months.
- Resistance$38.60
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Lyell Immunopharma, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $384.52M, is number 263 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $36K (down 41% year on year) and a loss of $274.45M.
- For fiscal 2026, analysts expect on average revenue of $12.25K (down 66%) and adjusted earnings per share of −$7.16.
Show more
- MEQIRI Score 33 out of 100 (Weak): rank 645 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $247.22M, financial debt $50.99M (fiscal 2025).Stability 67
Weaknesses
- Revenue shrinkingRevenue down 65.9% a year since 2020.Growth 32
- DilutionShare count up 39% since 2020.Capital allocation 18
- Loss-makingLoss of $255.16M over the last 12 months.Fundamentals 17
The score is held back by fundamentals and profitability.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 63.4% on the twelve months before. Revenue has declined since 2019 (-38% per year), so it is worth watching closely.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −31953%, operating −566039%, net −762356%. Last 12 months: net −100%.
Debt & balance sheet
Fiscal 2025Debt is low; no interest coverage is reported.
Earnings
- Next earnings
- 11 Mar 2027in 118 days
- Last reported
- 4 Nov 2026EPS reported −$1.86 (expected −$1.91)above expectations
Analyst estimates
Earnings estimates have barely changed since 9 Nov 2026.
- Earnings per share
- −$7.160.0%
- Revenue
- $12.25K0.0%
- Earnings per share
- −$7.270.0%
- Revenue
- $13.17K0.0%
MEQIRI has stored the estimates since 9 Nov 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $25M in total. 7 insiders sold, $258,697 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Lee Gary K.Sale
10 Nov 2026, Chief Scientific Officer
- Shares
- 129
- Price
- $15.93
- Value
- $2,055
- Hill Stephen J.Sale
10 Nov 2026, Chief Operating Officer
- Shares
- 88
- Price
- $15.93
- Value
- $1,402
- Seely LynnSale
10 Nov 2026, President and CEO
- Shares
- 545
- Price
- $15.93
- Value
- $8,682
Show 14 more
- Bulis Veronica SanchezSale
10 Nov 2026, VP, Corporate Controller
- Shares
- 416
- Price
- $15.93
- Value
- $6,627
- ARCH Venture Fund XIII, L.P., ARCH Venture Partners IX, LLCPurchase
4 Nov 2026, Major holder
- Shares
- 2,321,262
- Price
- $10.77
- Value
- $25M
- Aguirre Jarrad MattieuSale
12 Oct 2026, Chief Medical Officer
- Shares
- 422
- Price
- $8.63
- Value
- $3,642
- Shook DavidSale
10 Sept 2026, Chief Medical Officer
- Shares
- 500
- Price
- $12.70
- Value
- $6,350
- Seely LynnSale
21 Aug 2026, President and CEO
- Shares
- 9,589
- Price
- $15.54
- Value
- $149,013
- Hill Stephen J.Sale
21 Aug 2026, Chief Operating Officer
- Shares
- 989
- Price
- $15.54
- Value
- $15,369
- Lee Gary K.Sale
21 Aug 2026, Chief Scientific Officer
- Shares
- 1,457
- Price
- $15.54
- Value
- $22,642
- Bulis Veronica SanchezSale
10 Aug 2026, VP, Corporate Controller
- Shares
- 621
- Price
- $14.34
- Value
- $8,905
- Lee Gary K.Sale
10 Aug 2026, Chief Scientific Officer
- Shares
- 131
- Price
- $14.34
- Value
- $1,879
- Hill Stephen J.Sale
10 Aug 2026, Chief Operating Officer
- Shares
- 89
- Price
- $14.34
- Value
- $1,276
- Seely LynnSale
10 Aug 2026, President and CEO
- Shares
- 390
- Price
- $14.34
- Value
- $5,593
- Innovative Cellular Therapeutics Holdings LtdSale
17 Jul 2026, Major holder
- Shares
- 10
- Price
- $13.70
- Value
- $137
- Innovative Cellular Therapeutics Holdings LtdSale
16 Jul 2026, Major holder
- Shares
- 10
- Price
- $13.73
- Value
- $137
- Shook DavidSale
10 Jun 2026, Chief Medical Officer
- Shares
- 1,977
- Price
- $12.64
- Value
- $24,989
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Lyell Immunopharma
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 33
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Assembly BiosciencesASMB $410.88M34
- RezoluteRZLT $405.49M37
- X4 PharmaceuticalsXFOR $401.08M37
- ProKidneyPROK $386.69M27
- ARS PharmaceuticalsSPRY $383.01M33
- Fennec PharmaceuticalsFENC $382.23M56
- NeurogeneNGNE $377.68M32
- CorMedixCRMD $377.25M56
ETFs that hold Lyell Immunopharma
Held by 4 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.02% | 0.35% | €1.25B |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.02% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.01% | 0.40% | €813.42M |
Show 1 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.00% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.